Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression

Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational breast cancer research 2023, Vol.4, p.31-31
Hauptverfasser: Neven, Patrick, Dullens, Lieke, Han, Sileny, Deblander, Anne, Van Herck, Yannick, Van Houdt, Maxime, Wildiers, Hans
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 31
container_issue
container_start_page 31
container_title Translational breast cancer research
container_volume 4
creator Neven, Patrick
Dullens, Lieke
Han, Sileny
Deblander, Anne
Van Herck, Yannick
Van Houdt, Maxime
Wildiers, Hans
description
doi_str_mv 10.21037/tbcr-23-41
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3055892023</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-90872d28fdf4e446bc0b308beb6cf8ba87a9bb1fc807c4a73d3e1cf8b53de293</originalsourceid><addsrcrecordid>eNpVkU1LHTEUhodSqaKu3JcsCzKaj5mbTDeliO0tiIK4DyeZM2PKTDJNci_21_SvNrfeiq5ywvvw5IS3qs4YveCMCnmZjY01F3XD3lVHnDNVr6RU71_Nh9VpSj8ppUIwIVbsQ3UolGxZ03ZH1Z9b2LoRsvMj8fiU6xE9xnIPnqzvyTm5XF_fc1KTGTOkXAJLTMQyEgveYiT5sfCLw_SZALHRFQImYsM8o88Qf5NiAoMzWGcnZ8g2XZC8sa53PuyEBIZcNAtMJuyRJYYxYkpliZPqYIAp4en-PK4evl0_XK3rm7vvP66-3tSWS5rrjirJe66GfmiwaVbGUiOoMmhWdlAGlITOGDZYRaVtQIpeINslreiRd-K4-vKsXTZmxt6W1SNMeoluLl_QAZx-m3j3qMew1YzRTlC5M3zaG2L4tcGU9eySxWkCj2GTtKBtqzpOuSjo-TNqY0gp4vDyDqP6X6t616rmQjes0B9fr_bC_u9Q_AUYmqJ6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3055892023</pqid></control><display><type>article</type><title>Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Neven, Patrick ; Dullens, Lieke ; Han, Sileny ; Deblander, Anne ; Van Herck, Yannick ; Van Houdt, Maxime ; Wildiers, Hans</creator><creatorcontrib>Neven, Patrick ; Dullens, Lieke ; Han, Sileny ; Deblander, Anne ; Van Herck, Yannick ; Van Houdt, Maxime ; Wildiers, Hans</creatorcontrib><identifier>ISSN: 2218-6778</identifier><identifier>EISSN: 2218-6778</identifier><identifier>DOI: 10.21037/tbcr-23-41</identifier><identifier>PMID: 38751459</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><ispartof>Translational breast cancer research, 2023, Vol.4, p.31-31</ispartof><rights>2023 Translational Breast Cancer Research. All rights reserved. 2023 Translational Breast Cancer Research.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093079/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093079/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4021,27921,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38751459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neven, Patrick</creatorcontrib><creatorcontrib>Dullens, Lieke</creatorcontrib><creatorcontrib>Han, Sileny</creatorcontrib><creatorcontrib>Deblander, Anne</creatorcontrib><creatorcontrib>Van Herck, Yannick</creatorcontrib><creatorcontrib>Van Houdt, Maxime</creatorcontrib><creatorcontrib>Wildiers, Hans</creatorcontrib><title>Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression</title><title>Translational breast cancer research</title><addtitle>Transl Breast Cancer Res</addtitle><issn>2218-6778</issn><issn>2218-6778</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LHTEUhodSqaKu3JcsCzKaj5mbTDeliO0tiIK4DyeZM2PKTDJNci_21_SvNrfeiq5ywvvw5IS3qs4YveCMCnmZjY01F3XD3lVHnDNVr6RU71_Nh9VpSj8ppUIwIVbsQ3UolGxZ03ZH1Z9b2LoRsvMj8fiU6xE9xnIPnqzvyTm5XF_fc1KTGTOkXAJLTMQyEgveYiT5sfCLw_SZALHRFQImYsM8o88Qf5NiAoMzWGcnZ8g2XZC8sa53PuyEBIZcNAtMJuyRJYYxYkpliZPqYIAp4en-PK4evl0_XK3rm7vvP66-3tSWS5rrjirJe66GfmiwaVbGUiOoMmhWdlAGlITOGDZYRaVtQIpeINslreiRd-K4-vKsXTZmxt6W1SNMeoluLl_QAZx-m3j3qMew1YzRTlC5M3zaG2L4tcGU9eySxWkCj2GTtKBtqzpOuSjo-TNqY0gp4vDyDqP6X6t616rmQjes0B9fr_bC_u9Q_AUYmqJ6</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Neven, Patrick</creator><creator>Dullens, Lieke</creator><creator>Han, Sileny</creator><creator>Deblander, Anne</creator><creator>Van Herck, Yannick</creator><creator>Van Houdt, Maxime</creator><creator>Wildiers, Hans</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2023</creationdate><title>Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression</title><author>Neven, Patrick ; Dullens, Lieke ; Han, Sileny ; Deblander, Anne ; Van Herck, Yannick ; Van Houdt, Maxime ; Wildiers, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-90872d28fdf4e446bc0b308beb6cf8ba87a9bb1fc807c4a73d3e1cf8b53de293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Neven, Patrick</creatorcontrib><creatorcontrib>Dullens, Lieke</creatorcontrib><creatorcontrib>Han, Sileny</creatorcontrib><creatorcontrib>Deblander, Anne</creatorcontrib><creatorcontrib>Van Herck, Yannick</creatorcontrib><creatorcontrib>Van Houdt, Maxime</creatorcontrib><creatorcontrib>Wildiers, Hans</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational breast cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neven, Patrick</au><au>Dullens, Lieke</au><au>Han, Sileny</au><au>Deblander, Anne</au><au>Van Herck, Yannick</au><au>Van Houdt, Maxime</au><au>Wildiers, Hans</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression</atitle><jtitle>Translational breast cancer research</jtitle><addtitle>Transl Breast Cancer Res</addtitle><date>2023</date><risdate>2023</risdate><volume>4</volume><spage>31</spage><epage>31</epage><pages>31-31</pages><issn>2218-6778</issn><eissn>2218-6778</eissn><cop>China</cop><pub>AME Publishing Company</pub><pmid>38751459</pmid><doi>10.21037/tbcr-23-41</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2218-6778
ispartof Translational breast cancer research, 2023, Vol.4, p.31-31
issn 2218-6778
2218-6778
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093079
source PubMed Central Open Access; PubMed Central
title Navigating next-generation HR + /HER2 - metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T18%3A21%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Navigating%20next-generation%20HR%20+%20/HER2%20-%20metastatic%20breast%20cancer%20therapies:%20a%20critical%20commentary%20on%20abemaciclib%20vs.%20tucidinostat%20after%20palbociclib%20progression&rft.jtitle=Translational%20breast%20cancer%20research&rft.au=Neven,%20Patrick&rft.date=2023&rft.volume=4&rft.spage=31&rft.epage=31&rft.pages=31-31&rft.issn=2218-6778&rft.eissn=2218-6778&rft_id=info:doi/10.21037/tbcr-23-41&rft_dat=%3Cproquest_pubme%3E3055892023%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3055892023&rft_id=info:pmid/38751459&rfr_iscdi=true